New Antibody Offers Hope for Breast Cancer

Quick Smiles:

• A triple-engineered antibody could help patients whose breast cancers resist current treatments.
• This antibody strengthens immune cells’ activity against tumors, showing promise in lab studies.
• Future clinical trials aim to bring this innovative therapy to those in need.

A team at King’s College London has created a new antibody that not only attacks cancer cells directly, but also boosts the body’s immune system to fight back. This advanced therapy could offer new hope to patients with treatment-resistant and aggressive triple-negative breast cancers, where current options are limited.

Researchers describe the antibody as “triple-engineered” because it binds to cancer cells on one side, drawing in and activating immune cells on the other. Their experiments found that this design prompted immune cells already present in tumors to become more active and effective at targeting cancer.

Importantly, the modified antibody also energized immune cells circulating in the bloodstream, potentially improving the body’s overall defense against cancer.

“By making a few key changes in the structure of the antibody, we found that it could activate the immune system much more powerfully than any unmodified antibody currently used in breast cancer treatment,” said study first author Dr. Alicia Chenoweth.

“Many of the immune cells in breast tumors are in a ‘suppressed’ state, difficult to activate with unmodified antibodies. We found our triple-engineered antibodies were not only able to activate these immune cells to kill the cancer cells, but shifted these immune cells to a more ‘activated’ state overall.”

Professor Sophia Karagiannis, who led the study, explained, “By examining key immune cell receptors in breast tumors, including those tumors resistant to chemotherapy and immunotherapy, we have designed our antibody to make them interact better and harness the immune system in a way that has never been done or tested in cancer before.”

The new therapy could be tested in clinical trials soon and may one day help with other cancers, as the antibody targets exist in ovarian and endometrial cancers as well. Ongoing research is focused on making the treatment last longer in the body and enabling it to activate even more immune cells.

If these developments are successful, they could offer fresh hope for many patients who need more effective options—and inspire further breakthroughs for cancer care everywhere.

Source